Atrion Competitors

Atrion (NASDAQ:ATRI) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Insider and Institutional Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 22.4% of Atrion shares are owned by insiders. Comparatively, 1.2% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Atrion has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and Align Technology, as provided by MarketBeat.com.

Align Technology has a consensus target price of $502.1667, indicating a potential downside of 17.18%. Given Align Technology's higher probable upside, analysts plainly believe Align Technology is more favorable than Atrion.

Valuation & Earnings

This table compares Atrion and Align Technology's gross revenue, earnings per share and valuation.

Align Technology has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and Align Technology's net margins, return on equity and return on assets.

Summary

Align Technology beats Atrion on 10 of the 12 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Dividends

Atrion pays an annual dividend of $7.00 per share and has a dividend yield of 1.0%. West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and West Pharmaceutical Services has increased its dividend for 25 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and West Pharmaceutical Services, as provided by MarketBeat.com.

West Pharmaceutical Services has a consensus target price of $310.00, indicating a potential downside of 1.22%. Given West Pharmaceutical Services' higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Atrion.

Valuation & Earnings

This table compares Atrion and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

West Pharmaceutical Services has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and West Pharmaceutical Services' net margins, return on equity and return on assets.

Summary

West Pharmaceutical Services beats Atrion on 11 of the 15 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 1.4% of The Cooper Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Dividends

Atrion pays an annual dividend of $7.00 per share and has a dividend yield of 1.0%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and The Cooper Companies, as provided by MarketBeat.com.

The Cooper Companies has a consensus target price of $384.25, indicating a potential downside of 3.82%. Given The Cooper Companies' higher probable upside, analysts plainly believe The Cooper Companies is more favorable than Atrion.

Valuation & Earnings

This table compares Atrion and The Cooper Companies' top-line revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and The Cooper Companies' net margins, return on equity and return on assets.

Summary

The Cooper Companies beats Atrion on 8 of the 15 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

Atrion pays an annual dividend of $7.00 per share and has a dividend yield of 1.0%. DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and DENTSPLY SIRONA has increased its dividend for 1 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Atrion and DENTSPLY SIRONA's top-line revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and DENTSPLY SIRONA, as provided by MarketBeat.com.

DENTSPLY SIRONA has a consensus target price of $55.3333, indicating a potential downside of 15.42%. Given DENTSPLY SIRONA's higher probable upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Atrion.

Summary

Atrion beats DENTSPLY SIRONA on 9 of the 15 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by company insiders. Comparatively, 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.

Valuation and Earnings

This table compares Haemonetics and Atrion's revenue, earnings per share (EPS) and valuation.

Haemonetics has higher revenue and earnings than Atrion.

Profitability

This table compares Haemonetics and Atrion's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Haemonetics and Atrion, as provided by MarketBeat.

Haemonetics presently has a consensus target price of $144.80, indicating a potential upside of 23.79%. Given Haemonetics' higher probable upside, analysts plainly believe Haemonetics is more favorable than Atrion.

Summary

Haemonetics beats Atrion on 8 of the 12 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by company insiders. Comparatively, 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

STAAR Surgical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.

Valuation and Earnings

This table compares STAAR Surgical and Atrion's revenue, earnings per share (EPS) and valuation.

Atrion has higher revenue and earnings than STAAR Surgical.

Profitability

This table compares STAAR Surgical and Atrion's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for STAAR Surgical and Atrion, as provided by MarketBeat.

STAAR Surgical presently has a consensus target price of $68.50, indicating a potential downside of 42.05%. Given STAAR Surgical's higher probable upside, analysts plainly believe STAAR Surgical is more favorable than Atrion.